Arterra Bioscience (ARBS) Q1 2025 TU earnings summary

Executive summary

• Revenue for the quarter ended March 31, 2025, reached approximately €1.3 million, up 21.6% year-over-year.

• Growth driven by both cosmetic raw material sales and service revenues.

• Management expresses confidence in achieving planned objectives, citing strong order intake.

Financial highlights

• Total revenue for Q1 2025: €1,324,970, compared to €1,089,830 in Q1 2024 (+21.6%).

• Cosmetic raw material sales: €1,137,180, up 21.7% from €934,530 year-over-year.

• Service revenues: €187,790, up 20.9% from €155,300 year-over-year.

Outlook and guidance

• Management highlights a continued growth trend from 2024 and positive order momentum.

• Confidence expressed in meeting programmed targets for the year.